Literature DB >> 28209325

Japanese guidelines for atopic dermatitis 2017.

Ichiro Katayama1, Michiko Aihara2, Yukihiro Ohya3, Hidehisa Saeki4, Naoki Shimojo5, Shunsuke Shoji6, Masami Taniguchi7, Hidekazu Yamada8.   

Abstract

Given the importance of appropriate diagnosis and appropriate assessment of cutaneous symptoms in treatment of atopic dermatitis, the basics of treatment in this guideline are composed of (1) investigation and countermeasures of causes and exacerbating factors, (2) correction of skin dysfunctions (skin care), and (3) pharmacotherapy, as three mainstays. These are based on the disease concept that atopic dermatitis is an inflammatory cutaneous disease with eczema by atopic diathesis, multi-factorial in onset and aggravation, and accompanied by skin dysfunctions. These three points are equally important and should be appropriately combined in accordance with the symptoms of each patient. In treatment, it is important to transmit the etiological, pathological, physiological, or therapeutic information to the patient to build a favorable partnership with the patient or his/her family so that they may fully understand the treatment. This guideline discusses chiefly the basic therapy in relation to the treatment of this disease. The goal of treatment is to enable patients to lead an uninterrupted social life and to control their cutaneous symptoms so that their quality of life (QOL) may meet a satisfactory level. The basics of treatment discussed in this guideline are based on the "Guidelines for the Treatment of Atopic Dermatitis 2008" prepared by the Health and Labour Sciences Research and the "Guidelines for the Management of Atopic Dermatitis 2015 (ADGL2015)" prepared by the Atopic Dermatitis Guidelines Advisory Committee, Japanese Society of Allergology in principle. The guidelines for the treatment of atopic dermatitis are summarized in the "Japanese Guideline for the Diagnosis and Treatment of Allergic Disease 2016" together with those for other allergic diseases.
Copyright © 2017 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Atopic dermatitis; Exacerbating factors; Guideline; Pharmacotherapy; Skin care

Mesh:

Year:  2017        PMID: 28209325     DOI: 10.1016/j.alit.2016.12.003

Source DB:  PubMed          Journal:  Allergol Int        ISSN: 1323-8930            Impact factor:   5.836


  43 in total

Review 1.  "Inflammatory skin march" in atopic dermatitis and psoriasis.

Authors:  Masutaka Furue; Takafumi Kadono
Journal:  Inflamm Res       Date:  2017-06-15       Impact factor: 4.575

2.  Local allergic conjunctivitis: a phenotype of allergic conjunctivitis.

Authors:  Yasuo Yamana; Ken Fukuda; Ryota Ko; Eiichi Uchio
Journal:  Int Ophthalmol       Date:  2019-05-15       Impact factor: 2.031

3.  Effect of filaggrin loss-of-function mutations on atopic dermatitis in young age: a longitudinal birth cohort study.

Authors:  Ryota Koseki; Wataru Morii; Emiko Noguchi; Moena Ishikawa; Limin Yang; Kiwako Yamamoto-Hanada; Masami Narita; Hirohisa Saito; Yukihiro Ohya
Journal:  J Hum Genet       Date:  2019-06-28       Impact factor: 3.172

4.  Recent trends of ocular complications in patients with atopic dermatitis.

Authors:  Kaori Yamamoto; Yoshihiro Wakabayashi; Setsuko Kawakami; Takafumi Numata; Tomonobu Ito; Yukari Okubo; Ryoji Tsuboi; Hiroshi Goto
Journal:  Jpn J Ophthalmol       Date:  2019-06-26       Impact factor: 2.447

5.  A Serum Level of Squamous Cell Carcinoma Antigen as a Real-Time Biomarker of Atopic Dermatitis.

Authors:  Masaki Shimomura; Yuka Okura; Yutaka Takahashi; Ichiro Kobayashi
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2021-08-19       Impact factor: 0.885

Review 6.  National Saudi Consensus Statement on the Management of Atopic Dermatitis (2021).

Authors:  Mohammad I Fatani; Afaf A Al Sheikh; Mohammed A Alajlan; Ruaa S Alharithy; Yousef Binamer; Rayan G Albarakati; Khalidah A Alenzi; Amr M Khardaly; Bedor A Alomari; Hajer Y Almudaiheem; Ahmed Al-Jedai; Maysa T Eshmawi
Journal:  Dermatol Ther (Heidelb)       Date:  2022-07-04

Review 7.  Update on the Pathogenesis and Therapy of Atopic Dermatitis.

Authors:  Huaguo Li; Zhen Zhang; Hui Zhang; Yifeng Guo; Zhirong Yao
Journal:  Clin Rev Allergy Immunol       Date:  2021-08-02       Impact factor: 8.667

8.  Delftia acidovorans secretes substances that inhibit the growth of Staphylococcus epidermidis through TCA cycle-triggered ROS production.

Authors:  Tomotaka Ohkubo; Yasuhiko Matsumoto; Otomi Cho; Yuki Ogasawara; Takashi Sugita
Journal:  PLoS One       Date:  2021-07-02       Impact factor: 3.240

9.  Association of the incidence of atopic dermatitis until 3 years old with birth month and with sunshine duration and humidity in the first 6 months of life: Japan Environment and Children's Study.

Authors:  Hiroshi Yokomichi; Mie Mochizuki; Akiko Tsuchida; Reiji Kojima; Sayaka Horiuchi; Tadao Ooka; Yuka Akiyama; Kunio Miyake; Sanae Otawa; Ryoji Shinohara; Hidekuni Inadera; Zentaro Yamagata
Journal:  BMJ Open       Date:  2021-07-05       Impact factor: 2.692

10.  Difamilast, a selective phosphodiesterase 4 inhibitor, ointment in paediatric patients with atopic dermatitis: a phase III randomized double-blind, vehicle-controlled trial.

Authors:  H Saeki; N Baba; K Ito; D Yokota; H Tsubouchi
Journal:  Br J Dermatol       Date:  2021-11-01       Impact factor: 11.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.